|
Dual inhibition of DNA double strand break (DSB) repair and PI3K pathway with BEZ235 (BEZ) to sensitize refractory metastatic (met) triple negative breast cancer (TNBC) to nab paclitaxel/cisplatin (pac/cis) in a patient with an exceptional response (ExRx). |
|
|
Consulting or Advisory Role - Theranostics Health |
|
|
Stock and Other Ownership Interests - Theranostics Health |
Patents, Royalties, Other Intellectual Property - George Mason University |
|
|
|
|
|
Employment - Ashion Analytics; TGen |
|
|
Stock and Other Ownership Interests - Theranostics Health |
Consulting or Advisory Role - Theranostics Health |
Patents, Royalties, Other Intellectual Property - George Mason University |
|
|
Employment - Ashion Analytics; TGen |
|
|
|
|
|
Employment - Theranostics Health |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
No Relationships to Disclose |